Defined Flanking Spacers and Enhanced Proteolysis Is Essential for Eradication of Established Tumors by an Epitope String DNA Vaccine1

Loss of immunogenic epitopes by tumors has urged the development of vaccines against multiple epitopes. Recombinant DNA technologies have opened the possibility to develop multiepitope vaccines in a relatively rapid and efficient way. We have constructed four naked DNA-based multiepitope vaccines, containing CTL, Th cell, and B cell epitopes of the human papillomavirus type 16. Here we show that gene gun-mediated vaccination with an epitope-based DNA vaccine protects 100% of the vaccinated mice against a lethal tumor challenge. The addition of spacers between the epitopes was crucial for the epitope-induced tumor protection, as the same DNA construct without spacers was significantly less effective and only protected 50% of the mice. When tested for therapeutic potential, only the epitope construct with defined spacers significantly reduced the size of established tumors, but failed to induce tumor regression. Only after targeting the vaccine-encoded protein to the protein degradation pathway by linking it to ubiquitin, the vaccine-induced T cell-mediated eradication of 100% of 7-day established tumors in mice. The finding that defined flanking sequences around epitopes and protein targeting dramatically increased the efficacy of epitope string DNA vaccines against established tumors will be of importance for the further development of multiepitope DNA vaccines toward clinical application.

[1]  G. Fleuren,et al.  Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. , 1999, European journal of cancer.

[2]  L. Kinlen Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. , 1985, The American journal of medicine.

[3]  R. Schlegel,et al.  The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes , 1989, Journal of virology.

[4]  M. Feltkamp,et al.  Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.

[5]  S J Rodda,et al.  Mapping the major human T helper epitopes of tetanus toxin. The emerging picture. , 1993, Journal of immunology.

[6]  P. Greenberg,et al.  Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein , 1991, The Lancet.

[7]  F. Wiklund,et al.  Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. , 1999, The New England journal of medicine.

[8]  Virander S. Chauhan,et al.  "Universal" T helper cell determinants enhance immunogenicity of a Plasmodium falciparum merozoite surface antigen peptide. , 1992, Journal of immunology.

[9]  K. Münger,et al.  The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. , 1989, Science.

[10]  J. Kaplan,et al.  Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. , 1999, Journal of immunology.

[11]  J. Whitton,et al.  A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge , 1993, Journal of virology.

[12]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[13]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[14]  G Y Ishioka,et al.  Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. , 1999, Journal of immunology.

[15]  Fernando Rodriguez,et al.  DNA Immunization with Minigenes: Low Frequency of Memory Cytotoxic T Lymphocytes and Inefficient Antiviral Protection Are Rectified by Ubiquitination , 1998, Journal of Virology.

[16]  H. Schreiber,et al.  Active immunization against cancer cells: impediments and advances. , 1998, Seminars in oncology.

[17]  Genital human papillomavirus infection in female university students as determined by a PCR-based method. , 1991, JAMA.

[18]  D J Moss,et al.  Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  I. Frazer,et al.  A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Feltkamp,et al.  Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. , 1995, Journal of immunology.

[21]  P. Kloetzel,et al.  The cleavage preference of the proteasome governs the yield of antigenic peptides , 1995, The Journal of experimental medicine.

[22]  Catia,et al.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E , 1992, The Journal of experimental medicine.

[23]  A. Levine,et al.  Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.

[24]  S. H. van der Burg,et al.  Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors , 1995, European journal of immunology.

[25]  S. Wilczynski,et al.  A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  A Sette,et al.  Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. , 1994, Journal of immunology.

[27]  B. Moss,et al.  Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination , 1988, Journal of virology.

[28]  W Keilholz,et al.  Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Drijfhout,et al.  Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[30]  Anderson Ll,et al.  Multivalent minigene vaccines against infectious disease. , 1999 .

[31]  E. Wherry,et al.  Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. , 1997, Journal of immunology.

[32]  P. Kloetzel,et al.  The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope , 1998, The Journal of experimental medicine.

[33]  P M Kloetzel,et al.  Abrogation of CTL Epitope Processing by Single Amino Acid Substitution Flanking the C-Terminal Proteasome Cleavage Site1 , 2000, The Journal of Immunology.

[34]  E. Gilboa,et al.  Induction of Cytotoxic T Lymphocytes With Dendritic Cells Transfected With Human Papillomavirus E6 and E7 RNA: Implications for Cervical Cancer Immunotherapy , 2000, Journal of immunotherapy.

[35]  D. Carson,et al.  Costimulation provided by DNA immunization enhances antitumor immunity. , 1997, Journal of immunology.

[36]  P. Kloetzel,et al.  A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome. , 1999, Journal of molecular biology.

[37]  R. Germain,et al.  Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization , 1998, The Journal of experimental medicine.

[38]  S. Childs Aztreonam in the treatment of urinary tract infection. , 1985, The American journal of medicine.

[39]  Scott R. Burrows,et al.  Targeting a Polyepitope Protein Incorporating Multiple Class II-Restricted Viral Epitopes to the Secretory/Endocytic Pathway Facilitates Immune Recognition by CD4+ Cytotoxic T Lymphocytes: a Novel Approach to Vaccine Design , 1998, Journal of Virology.

[40]  V. Cerundolo,et al.  Effect of epitope flanking residues on the presentation of N‐terminal cytotoxic T lymphocyte epitopes , 1999, European journal of immunology.

[41]  A. Hill,et al.  Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors. , 1997, Journal of immunological methods.

[42]  R. Webster,et al.  DNA vaccines. , 1996, AIDS research and human retroviruses.

[43]  H. Grey,et al.  Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. , 1995, Journal of immunology.

[44]  K. Münger,et al.  The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A , 1988, Cell.

[45]  D. Chargelegue,et al.  Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus. , 1999, The Journal of general virology.

[46]  F. Marincola,et al.  Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[48]  I. Frazer,et al.  Identification of B epitopes in human papillomavirus type 16 E7 open reading frame protein. , 1990, The Journal of general virology.

[49]  A. Suhrbier,et al.  Multi‐epitope DNA vaccines , 1997, Immunology and cell biology.

[50]  D. Bigner,et al.  Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors , 1997, The Journal of experimental medicine.

[51]  U. Koszinowski,et al.  Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein , 1991, Cell.